Boston, MA 04\/07\/2014 (wallstreetpr) –\u00a0When IsoRay, Inc. (NYSEMKT:ISR)<\/b> plunged into the field of developing treatment solutions for cancer, there was no telling how long it would take to bring a product to the market and how that product might change the fortunes of the company. But following recent developments, it is not easy to doubt that the company is poised for big harvest in cancer treatment.<\/p>\n
Following the Food and Drug Administration approval of the product of treatment of tumor, excitement is building up in the company as physicians take advantage of the treatment to return hope to cancer patients. The product is mostly finding application in the treatment of prostate cancer.<\/p>\n
Unlike other cancer therapies available in the market, Cesium-131 not only boasts of its efficacy, but it also results in safe operations which result into patient longevity and improved life quality. In other words, the treatment is winning the confidence of physicians in dealing with prostate cancer cases. The series of successful application of the technology has time and again placed IsoRay, Inc. (NYSEMKT:ISR) on the headlines.<\/p>\n
Dependable procedure<\/b><\/p>\n
Physicians seek the best for their patients, and they are also turning out to be the best partners for IsoRay. The prostate cancer treatment solution which IsoRay, Inc. (NYSEMKT:ISR) provides, allows physicians to directly put specific radiation dosage in locations where cancer may remain after tumor is removed. This is done by placing the Cesium-131 seed within the area targeted. The ability to put specific radiation dosage ensures that risks of damaging surrounding tissues are reduced. This makes the technology far much safer than alternative treatments.<\/p>\n
It has been established that the cancer products which IsoRay, Inc. (NYSEMKT:ISR) provides are able to significantly diminish the reoccurrence of tumor. This means that patients are able to gain quality and longer life after the first procedure.<\/p>\n
Financial benefit<\/b><\/p>\n
Cancer is a deadly disease, being responsible for many deaths today. But breakthrough technologies are still needed to tackle the disease. That IsoRay, Inc. (NYSEMKT:ISR) has edged closer to proving a dependable cancer treatment product puts the company at the heart of a huge potential financial opportunity.<\/p>\n
If spending on cancer treatment is anything to go by, increasing adoption of IsoRay\u2019s cancer treatment products means that the company is poised to generate significant revenue from the sale of the products. Moreover, the company\u2019s network of partners and customers is able to expand the market of the cancer treatments.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 04\/07\/2014 (wallstreetpr) –\u00a0When IsoRay, Inc. (NYSEMKT:ISR) plunged into the field of developing treatment solutions for cancer, there was no telling how long it […]<\/p>\n","protected":false},"author":13,"featured_media":18169,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5326,5327],"stock_ticker":[],"class_list":["post-18811","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-isoray-inc-nysemktisr","tag-nysemktisr","entry"],"acf":[],"yoast_head":"\n